{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:08Z","timestamp":1787067728327,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background\u2014<\/jats:title>\n                    <jats:p>Many hospitalized medically ill patients are at risk of venous thromboembolism (VTE). Risk factors include prior VTE, older age, immobility, obesity, cardiac or respiratory failure, and cancer (at-risk patients). Although guidelines recommend use of VTE prophylaxis for at-risk patients, many may not receive it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results\u2014<\/jats:title>\n                    <jats:p>Using a database linking admission records from &gt;150 US hospitals to health insurance claims, we identified people \u226540 years of age, hospitalized from 2003 to 2008. We excluded patients who: (1) were treated for VTE or hospitalized in the previous 30 days; (2) were admitted for traumatic injury or surgery; (3) had hypercoagulability at admission; or (4) received therapeutic dosages of low-molecular weight heparin, unfractionated heparin, or fondaparinux at admission. We examined the use of VTE prophylaxis (both pharmacological and nonpharmacological) on day 1 or 2 in hospital among at-risk patients; predictors of receipt of prophylaxis were examined using multivariate logistic regression. The study population consisted of 49 948 patients, of whom 34 374 (69%) were at risk. Only 18% of at-risk patients received VTE prophylaxis on day 1 or 2 in hospital, typically with low-molecular weight heparin (56% of patients receiving prophylaxis), intermittent pneumatic compression (25%), warfarin (16%), or graduated compression stockings (11%). Use of prophylaxis exceeded 25% only in patients admitted from nursing homes and those with prior VTE. Although there were several significant predictors of receipt of VTE prophylaxis, model discrimination was relatively poor (C-statistic=0.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion\u2014<\/jats:title>\n                    <jats:p>The majority of at-risk hospitalized medically ill patients do not receive VTE prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circoutcomes.112.965939","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T08:40:48Z","timestamp":1357720848000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Prophylaxis Against Venous Thromboembolism in Hospitalized Medically Ill Patients"],"prefix":"10.1161","volume":"6","author":[{"given":"Trudy","family":"Pendergraft","sequence":"first","affiliation":[{"name":"From the Policy Analysis Inc, Brookline, MA (T.P., J.E., G.O.); Pfizer, Inc, New York, NY (X.L., L.Z.L.); School of Medicine, Indiana University, Indianapolis, IN (X.L.); Bristol-Myers Squibb, Princeton, NJ (H.P.); Vertex Pharmaceuticals, Inc, Cambridge, MA (M.V.-L.); and Weill Medical College, Cornell University, New York, NY (L.Z.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianchen","family":"Liu","sequence":"additional","affiliation":[{"name":"From the Policy Analysis Inc, Brookline, MA (T.P., J.E., G.O.); Pfizer, Inc, New York, NY (X.L., L.Z.L.); School of Medicine, Indiana University, Indianapolis, IN (X.L.); Bristol-Myers Squibb, Princeton, NJ (H.P.); Vertex Pharmaceuticals, Inc, Cambridge, MA (M.V.-L.); and Weill Medical College, Cornell University, New York, NY (L.Z.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Edelsberg","sequence":"additional","affiliation":[{"name":"From the Policy Analysis Inc, Brookline, MA (T.P., J.E., G.O.); Pfizer, Inc, New York, NY (X.L., L.Z.L.); School of Medicine, Indiana University, Indianapolis, IN (X.L.); Bristol-Myers Squibb, Princeton, NJ (H.P.); Vertex Pharmaceuticals, Inc, Cambridge, MA (M.V.-L.); and Weill Medical College, Cornell University, New York, NY (L.Z.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Phatak","sequence":"additional","affiliation":[{"name":"From the Policy Analysis Inc, Brookline, MA (T.P., J.E., G.O.); Pfizer, Inc, New York, NY (X.L., L.Z.L.); School of Medicine, Indiana University, Indianapolis, IN (X.L.); Bristol-Myers Squibb, Princeton, NJ (H.P.); Vertex Pharmaceuticals, Inc, Cambridge, MA (M.V.-L.); and Weill Medical College, Cornell University, New York, NY (L.Z.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Vera-Llonch","sequence":"additional","affiliation":[{"name":"From the Policy Analysis Inc, Brookline, MA (T.P., J.E., G.O.); Pfizer, Inc, New York, NY (X.L., L.Z.L.); School of Medicine, Indiana University, Indianapolis, IN (X.L.); Bristol-Myers Squibb, Princeton, NJ (H.P.); Vertex Pharmaceuticals, Inc, Cambridge, MA (M.V.-L.); and Weill Medical College, Cornell University, New York, NY (L.Z.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry Z.","family":"Liu","sequence":"additional","affiliation":[{"name":"From the Policy Analysis Inc, Brookline, MA (T.P., J.E., G.O.); Pfizer, Inc, New York, NY (X.L., L.Z.L.); School of Medicine, Indiana University, Indianapolis, IN (X.L.); Bristol-Myers Squibb, Princeton, NJ (H.P.); Vertex Pharmaceuticals, Inc, Cambridge, MA (M.V.-L.); and Weill Medical College, Cornell University, New York, NY (L.Z.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"Oster","sequence":"additional","affiliation":[{"name":"From the Policy Analysis Inc, Brookline, MA (T.P., J.E., G.O.); Pfizer, Inc, New York, NY (X.L., L.Z.L.); School of Medicine, Indiana University, Indianapolis, IN (X.L.); Bristol-Myers Squibb, Princeton, NJ (H.P.); Vertex Pharmaceuticals, Inc, Cambridge, MA (M.V.-L.); and Weill Medical College, Cornell University, New York, NY (L.Z.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.11.1102"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.11.1245"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0656"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2296"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2993"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60202-0"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.526"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1296-y"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20360"},{"key":"e_1_3_4_11_2","unstructured":"The Joint Commission on the Accreditation of Healthcare Organizations. Venous thromboembolism (VTE) core measure set. 2009."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.01.011"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-09-0667"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111288"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-1-201007060-00004"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110899"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-9-201111010-00008"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-9-201111010-00011"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.112.965939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T22:37:44Z","timestamp":1715553464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.112.965939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.112.965939"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.112.965939","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"2012-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-11-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}